Celgene exec Chris Hugin linked to $280 M settlement and political attacks over Revlimid price hikes

i"}, {"range™: {"length":394,"start":0},"textStyle":"_ anf-ts-1"}],"layout":"default-— body", "role": "body", "text":"An examination of Celgened€™s aggressive promotion of Revlimid and its predecessor, Thalomid, while Mr. Hugin was a top executive at the company, including its chief executive for six years, reveals many of the controversial financial and legal tactics that have tarnished the industryd€™s reputation, from marketing drugs for unapproved uses to raising prices and fighting off generic competitors.", "type": "text"}, {("additions": [{"URL":"https://www.nytimes.com/2017/07/25/h ealth/celgene-to-pay-280-million-to-settle-fraud-suit-over-cancer drugs.html?partner=applenewsé&ad keywords=APPLEMOBILE&region=written throughé&asset_id=100000006090758", "range™: {"length" 793, "Start":19}, "type"? "Link" }],"identifier":" ant-body— 12", "inlineTextStyles":[{"range":{"length":362,"start":0},"textStyle":" anf-ts- im}, {"range":{"Llength":362,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"Last year, Celgene paid $280 million to settle a whistle- blower lawsuit claiming it had inappropriately promoted Revlimid and Thalomid to treat a range of cancers beyond what the Food and Drug Administration had approved. Several generic drug companies have sued the company claiming that Celgene denied them access to drug samples needed to make cheaper copies.","type™:"text"}, {"additions": [{"URL":"https://www. youtube.com/watch?v=RIfsé6hthw Go", "range": {"length":71, "start ":138},"type":"Link"}],"identifier":" anf-body- 13","inlineTextStyles": [{"range":{"length":334,"start":0},"textStyle":" anf-ts- I"}, {"range™: {"length":334,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"Mr. Hugin has also been targeted by a super PAC run by a cancer patient taking Revlimid that launched a $1.5 million advertising campaign criticizing steep price hikes of cancer drugs during Mr. Hugind€™s tenure at Celgen And the Menendez campaign has attacked him around drug prices, personal profits and the $280 million settlement.","type":"text"}, {"bannerType":"any","identifier":" anf- banner advertisement-2","layout": "ComponentLayout— 4","role":"banner advertisement", "type":"banner advertisement"}, {"identifier"™:" anf- body-14", "inlineTextStyles": [{"range"™:{"length":38,"start":0},"textStyle":" anf-ts- I"}, {"range™: {"length":38,"start":0},"textStyle":" anf-ts-1"}],"layout":"default— body", "role":"body", "text":"Mr. Hugin has dismissed the criticism.","type":"text"}, {"identifier":" anf-body- 15","inlineTextStyles":[{"range":{"length":317,"start":0},"textStyle":" anf-ts- i"}, {"range"™:{"length":317,"start":0},"textStyle":" anf-ts-1"}],"layout":"default-— body", "role": "body", "text": "a€eNew Jersey voters are a lot smarter than my opponent gives them credit for,d4€ Mr. Hugin said in a statement. A4€eThey understand that it costs billions of dollars in research and development, and years of hard work by hundreds of researchers and scientists, to develop medicines that successfully treat and cure cancer.a€","type":"text"}, {"identifier":" anf-body- 16", "inlineTextStyles":[{"range":{"length":237,"start":0},"textStyle":" anf-ts- I"}, {"range™: {"length":237,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-— body", "role":"body", "text":"Some experts are not so sure. Patrick Murray, director of the Monmouth University Poll, noted that despite the fact that many large drug companies are based in New Jersey, public opinion in the state likely mirrors the national attitude.","type"™:"text"}, {"identifier":" anf-body- 17","inlineTextStyles": [{"range":{"length":228,"start":0},"textStyle":" anf-ts- i"}, {"range"™: {"length":228,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text": "a€eConcern about being able to afford health care is the top issue mentioned by voters in our polling for this yeara€™s midterm, in large part because of rising drug costs,a4€ Mr. Murray said. d€eThis provides an opening for Menendez. ae™mae™", "type™:"text"}, {"components": [{"caption":"Mr. Menendez has attacked Mr. Hugind€™s record as a pharmaceutical executive, accusing him of profiting from major price increases for cancer drugs. Bryan Anselm for The New York Times", "captionComponent":{"text":"Mr. Menendez has attacked Mr. Hugind€™s record as a pharmaceutical executive, accusing him of profiting from major price increases for cancer drugs. Bryan Anselm for The New York Times"},"identifier™:"100000006098032 Sba8b804lidfc", "imageIdentifier":"5e5526aaedbd7aft 8c8bhade0a70blidad", "layout":"fullbleed- image", "role":"photo", "type": "scalable image"}, {"identifier":" anf-caption- 2","inlineTextStyles": [{"range": {"length":36, "start":146}, "textStyle": "photo- credit"}],"layout":"default-caption", "role": "caption", "text":"Mr. Menendez has attacked Mr. Hugind€™s record as a pharmaceutical executive, accusing him of profiting from major price increases for cancer drugs. Bryan Anselm for The New York Times ","type™:"text"}],"identifier":" anf-container-1", "layout": "image- container", "role":"container", "type":"container"}, {"identifier":" anf-body- 18","inlineTextStyles":[{"range":{"length":277,"start":0},"textStyle":" anf-ts- HOUSE_OVERSIGHT_028416